Bayesian Phase II optimization for time-to-event data based on historical information

Statistical Methods in Medical Research
Anja BertscheGerhard Nehmiz

Abstract

After exploratory drug development, companies face the decision whether to initiate confirmatory trials based on limited efficacy information. This proof-of-concept decision is typically performed after a Phase II trial studying a novel treatment versus either placebo or an active comparator. The article aims to optimize the design of such a proof-of-concept trial with respect to decision making. We incorporate historical information and develop pre-specified decision criteria accounting for the uncertainty of the observed treatment effect. We optimize these criteria based on sensitivity and specificity, given the historical information. Specifically, time-to-event data are considered in a randomized 2-arm trial with additional prior information on the control treatment. The proof-of-concept criterion uses treatment effect size, rather than significance. Criteria are defined on the posterior distribution of the hazard ratio given the Phase II data and the historical control information. Event times are exponentially modeled within groups, allowing for group-specific conjugate prior-to-posterior calculation. While a non-informative prior is placed on the investigational treatment, the control prior is constructed via the meta-an...Continue Reading

References

Mar 1, 1976·Journal of Chronic Diseases·S J Pocock
Mar 1, 1986·Controlled Clinical Trials·D J SpiegelhalterP R Blackburn
Feb 19, 2005·Journal of Clinical Epidemiology·Lillian SungGeorge A Tomlinson
Jan 21, 2006·Clinical Trials : Journal of the Society for Clinical Trials·Peter F ThallNizar M Tannir
Sep 4, 2007·Biometrics·Satoshi MoritaPeter Müller
Feb 17, 2010·Clinical Trials : Journal of the Society for Clinical Trials·Beat NeuenschwanderDavid J Spiegelhalter
May 24, 2012·Statistical Methods in Medical Research·M Amper GamaloRam C Tiwari
Aug 6, 2013·Pharmaceutical Statistics·Kert VieleLaura Thompson
Aug 21, 2013·Journal of Biopharmaceutical Statistics·Kevin J Carroll
Sep 17, 2013·Pharmaceutical Statistics·Thomas GsponerHeinz Schmidli
Jan 11, 2014·Nature Biotechnology·Michael HayJesse Rosenthal
Jun 11, 2014·Journal of Biopharmaceutical Statistics·Heiko GötteGiacomo Mordenti
Oct 23, 2014·Pharmaceutical Statistics·Dennis LendremJohn D Isaacs
Dec 30, 2014·Statistics in Medicine·Matteo Cellamare, Valeria Sambucini
Apr 14, 2015·Pharmaceutical Statistics·Rosalind J WalleyPhil Woodward
Jul 19, 2015·Contemporary Clinical Trials·Daniel F HeitjanGui-Shuang Ying
Aug 8, 2015·Statistics in Medicine·Adriani NikolakopoulouGeorgia Salanti
Aug 11, 2015·Statistics in Medicine·Marietta KirchnerArmin Schüler
Sep 29, 2015·Pharmaceutical Statistics·Heiko GötteMeinhard Kieser
Jan 23, 2016·Pharmaceutical Statistics·Andrew P Grieve
Mar 19, 2016·Pharmaceutical Statistics·Paul FrewerJames Matcham
Apr 27, 2016·Statistics in Medicine·Ying YuanAmir Jazaeri
Oct 27, 2016·The New England Journal of Medicine·Brian L StromBartha M Knoppers
Jan 1, 2015·Therapeutic Innovation & Regulatory Science·Roland FischHeinz Schmidli

❮ Previous
Next ❯

Citations

Jan 30, 2021·Contemporary Clinical Trials Communications·Lucie BiardSylvie Chevret

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.